Cerenome secures national in-network agreement with Aetna for CNSide tests
CNSY•Cerenome's CNSide Diagnostics signed a national in-network agreement with Aetna, effective November 1, 2026. The deal adds approximately 26 million members, bringing contracted coverage to approximately 190 million lives across approximately 85% of US private payers.
1. Agreement expands coverage
Cerenome's CNSide Diagnostics signed a national in-network agreement with Aetna, effective November 1, 2026. It is CNSide's first national payer contract covering both tumor cell enumeration and molecular profiling. The agreement adds approximately 26 million members, bringing contracted coverage to approximately 190 million lives across approximately 85% of US private payers.
